Martek Biosciences (MATK) Tops Q2 EPS by 4c; Guides
Martek Biosciences Corporation (Nasdaq: MATK) reports Q2 EPS of $0.33, 4 cents better than the analyst estimate of $0.. Revenue for the quarter was $92.4 million, versus the consensus of $89.4 million.
Martek Biosciences sees FY EPS of $1.20-$1.25, versus the consensus of $1.23. Sees FY revenues of $350-$355 million, versus the consensus of $365.1 million.
Martek Biosciences sees FY EPS of $1.20-$1.25, versus the consensus of $1.23. Sees FY revenues of $350-$355 million, versus the consensus of $365.1 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Hewlett-Packard Company (HPQ) Tops Q2 EPS by 7c; Guides Q3 Below the Street, Raises FY12 Outlook
- UPDATE: NetApp, Inc. (NTAP) Tops Q4 EPS by 3c; Guides Q1 Lower
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
